The Launch of Once-Daily Pill Gives New Hope for Epilepsy Patients

Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission. Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial onset of seizures - the most common form of the disease. The new therapy is the first approved epilepsy treatment to selectively target AMPA receptors,... To continue reading this story Click Here